In an analysis of the TCR repertoire in ESCC patients, baseline peripheral CD8+ TCR diversity, increased tumor-peripheral Morisita–Horn overlap during treatment and sustained intratumoral T cell clones during treatment were predictive of survival improvement from combination therapy [163]. This evidence concerns the gene CD8A and neoplasm.